Tysabri (natalizumab) – study how Tysabri effects quality of life in multiple sclerosis
Department of Neurology,
Mellen Center for Multiple Sclerosis Treatment and Research,
Cleveland ... more »
|
|||
|
Multiple Sclerosis Info
If you want this blog to continue, than make it financialy viable for Bonnie to continue it. She puts in 2-3 hours a day into this blog, and spends money on it for it's upkeep.
Search
This Month
|
Wednesday, October 31
by
All About MS
on Wed 31 Oct 2007 09:00 AM CST
Tysabri (natalizumab) – study how Tysabri effects quality of life in multiple sclerosis
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland ... more »
by
All About MS
on Wed 31 Oct 2007 07:59 AM CST
Vavici™ Announces Formation of First Comprehensive International Distribution System for Stem Cell Therapies NEW YORK--(BUSINESS WIRE)— Vavici has announced its plans to create ... more »
by
All About MS
on Wed 31 Oct 2007 07:57 AM CST
Disease Activity Increases After MS Patients Stop Natalizumab (Tysabri) Treatment ST. PAUL, MN -- September 12, 2007 -- People with multiple sclerosis (MS) who ... more » Tuesday, October 30
by
All About MS
on Tue 30 Oct 2007 08:00 AM CST
Monday, October 29
by
All About MS
on Mon 29 Oct 2007 11:50 AM CST
VITAMIN D SUPPLEMENTS APPEAR TO BE ASSOCIATED WITH LOWER RISK OF DEATH CHICAGO—Individuals who take vitamin D supplements appear to have a lower risk of ... more » Sunday, October 28
by
All About MS
on Sun 28 Oct 2007 12:00 AM CST
Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple Sclerosis (RRMS)... more » Saturday, October 27
by
All About MS
on Sat 27 Oct 2007 08:18 AM CST
Multiple Sclerosis Society of Canada Oct 25, 2007 12:30 ET Multiple Sclerosis Society of Canada: Acne Medication May Delay Progress of Multiple Sclerosis
by
All About MS
on Sat 27 Oct 2007 07:51 AM CST
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE® is More Cost Effective Than Tysabri® for Treatment of Relapsing-Remitting Multiple Sclerosis Markov Model ... more » |
||